Familial hypercholesterolaemia: A look back, a look ahead

Medical Journal of Australia

Volumn 182, Issue 11, 2005, Pages 552-553

  Burnett, John R ^a   Ravine, David ^a   van Bockxmeer, Frank M ^b   Watts, Gerald F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; COLESTYRAMINE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PRAVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; AUSTRALIA; CLINICAL TRIAL; CORONARY RISK; DRUG DOSE REGIMEN; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; HUMAN; ISCHEMIC HEART DISEASE; SCREENING;

EID: 20444441974     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2005.tb06810.x     Document Type: Editorial

References (13)

1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
2. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003; 111: 1795-1803.
3. de Jongh S, Lilien MR, op't Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2117-2121.
4. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-medial thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004; 263: 369-370.
5. Whitfield AJ, Barrett PHR, van Bockxmeer FM, Burnett JR. Lipid disorders and mutations in the APOB gene. Clin Chem 2004; 50: 1725-1732.
6. Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001; 292: 1394-1398.
7. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. A randomized controlled trial. JAMA 2004; 292: 331-337.
8. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised double blind trial. Lancet 2001; 357: 577-581.
9. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007-3012.
10. Davidson MH, Toth PP. Combination therapy in the management of complex dyslipidemias. Curr Opin Lipidol 2004; 15: 423-431.
11. Marks D, Wonderling D, Thorogood M, et al. A cost effectiveness analysis of different approaches to screening for familial hypercholesterolaemia. BMJ 2002; 324: 1303-1306.
12. Civeira F, on behalf of the International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous hypercholesterolemia. Atherosclerosis 2004; 173: 55-68.
13. Thorsson B, Sigurdsson G, Gudnason V. Systematic family screening for familial hypercholesterolemia in Iceland. Arterioscler Thromb Vasc Biol 2003; 23: 335-338.